… in EGFR mutation frequency between gefitinib responders (5/5) … the gefitinib responders and
unselected US NSCLC patients (5/5 … The EGFR L858R mutation, previously observed in the …

… lung cancer (NSCLC). This study aimed to compare their clinical uses and the influence of
EGFR mutation… a large population of NSCLC patients with gefitinib and erlotinib in order to …

… mutation may cause acquired resistance to gefitinib. Our patient had concomitant T790M and
L858R EGFR mutations in … resistance to gefitinib — a finding implying that a mutation in the …

… of a patient with EGFR-mutant, gefitinib-responsive, advanced non–small-cell lung cancer
who had a relapse after two years of complete remission during treatment with gefitinib. The …

… in which patients received gefitinib therapy for NSCLC. From … during gefitinib treatment,
evaluated the efficacy of gefitinib, … efficacy of gefitinib in brain metastases and EGFR mutations. …

… gefitinib as well as the relationship between response and EGFR mutation in a series of
Chinese patients … study, four patients with disease control also had EGFR gene mutation, which …

… In our study the rate of the EGFR mutations in NSCLC patients was 9.4%. This study also
confirmed the benefits of firstand subsequent-lines of gefitinib administration in this patient …

… of gefitinib and erlotinib in second-line therapy of Asian NSCLC patients with activating EGFR
mutations (6)… and gefitinib in first-line treatment of NSCLC patients with common activating …

… gefitinib in NSCLC patients with uncommon EGFR mutations, we analyzed the data of 114
patients in the gefitinib group and 111 patients … patients who had uncommon EGFR mutations …

… of patients with mutated-EGFR non–small-cell lung cancer are … that selecting patients on
the basis of EGFR mutations rather … result in a population with a greater sensitivity to gefitinib. …